- Hillstream BioPharma Inc HILS signed an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein.
- The MUC1 gene was identified by Dr. Donald Kufe, Physician and Researcher at Dana-Farber, based on its overexpression in human cancers.
- Dr. Kufe has demonstrated that MUC1-C is necessary for multiple cancer cell hallmarks.
- Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc certain of its proprietary technology, which, if converted to an exclusive license agreement.
- The agreement will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream's Quatramer-based lead candidate HSB-1216 targeting CSC by ferroptosis induction. Combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long-term responses and cures.
- Price Action: HILS shares are up 114.60% at $1.44 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
